What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
Yelena Janjigian, MD
PeerYelena Janjigian, MD
PeerClaudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
PeerYelena Janjigian, MD
PeerWhat Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
Samuel J. Klempner, MD
PeerWhat Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
Yelena Janjigian, MD
PeerRoy F. Chemaly, MD, MPH
PeerKathleen Moore, MD, MS
PeerKathleen Moore, MD, MS
PeerSusana Banerjee, MBBS, MA, FRCP, PhD
Peer